RNA sequencing technology was employed to analyze differentially expressed genes after 24 h and 48 h of BMN673 treatment and delve deeper into the anticancer mechanisms of BMN673 beyond its synthetic lethal effect in ATM-deficient CRC cells. This evidence concerns the gene ATM and colorectal carcinoma.